Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt.

Q2 Medicine

Oman Medical Journal Pub Date : 2024-09-30 eCollection Date: 2024-09-01 DOI:10.5001/omj.2024.107

Nevin Hammam, Doaa Mosad, Amira M Ibrahim, Yousra H Abdel-Fattah, Hany M Aly, Hanan M El-Saadany, Maha Nassr, Abdelhafeez Moshrif, Hanan M Fathi, Samah I Nasef, Faten Ismail, Rawhya R El Shereef, Osman Hammam, Mervat I Abd-Elazeem, Enas A Abdelaleem, Abdelrahman Mohamed Elsayed, Samar Tharwat, Tamer A Gheita

{"title":"Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt.","authors":"Nevin Hammam, Doaa Mosad, Amira M Ibrahim, Yousra H Abdel-Fattah, Hany M Aly, Hanan M El-Saadany, Maha Nassr, Abdelhafeez Moshrif, Hanan M Fathi, Samah I Nasef, Faten Ismail, Rawhya R El Shereef, Osman Hammam, Mervat I Abd-Elazeem, Enas A Abdelaleem, Abdelrahman Mohamed Elsayed, Samar Tharwat, Tamer A Gheita","doi":"10.5001/omj.2024.107","DOIUrl":null,"url":null,"abstract":"Objectives: To investigate the incidence and associated risk factors of adverse events following COVID-19 vaccination in patients with inflammatory and non-inflammatory rheumatic and musculoskeletal diseases (I-RMD and NI-RMD, respectively).Methods: The Egyptian College of Rheumatology COVID-19 Study Group investigated physician-reported data (ECR-VaXurvey3) of RMD patients vaccinated against COVID-19 from December 2021 to June 2022, including their demographics, vaccination type, RMD diagnosis, treatments, post-vaccine flares, and other adverse events. The control group consisted of healthy, vaccinated individuals.Results: The ECR-VaXurvey3 included 890 vaccinated RMD patients, predominantly women (73.3%) with a mean age of 44.4 ± 12.1 years, and 172 controls. The RMD group comprised 816 (91.7%) with I-RMD and 74 (8.3%) with NI-RMD. The frequency of adverse events was comparable between the RMD and control groups. In RMD patients, injection site pain (59.9%) was the most reported adverse event. Post-vaccination COVID-19 infections and disease flares were reported in 2.9% and 12.1% of I-RMD patients and in 8.1% and 9.5% of NI-RMD patients (p = 0.018 and p = 0.497, respectively). The severity of prior COVID-19 infection (odds ratio (OR) = 2.4, 95% CI: 1.0-5.8; p = 0.040) and azathioprine use (OR = 2.6, 95% CI: 1.1-5.9; p = 0.024) were associated with higher post-vaccine adverse events, while biologic use was associated with fewer adverse events (OR = 0.5, 95% CI: 0.3-0.8; p = 0.010).Conclusions: Adverse events following COVID-19 vaccinations in patients with RMD are comparable to controls.","PeriodicalId":19667,"journal":{"name":"Oman Medical Journal","volume":"39 5","pages":"e676"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973885/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oman Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5001/omj.2024.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To investigate the incidence and associated risk factors of adverse events following COVID-19 vaccination in patients with inflammatory and non-inflammatory rheumatic and musculoskeletal diseases (I-RMD and NI-RMD, respectively).

Methods: The Egyptian College of Rheumatology COVID-19 Study Group investigated physician-reported data (ECR-VaXurvey3) of RMD patients vaccinated against COVID-19 from December 2021 to June 2022, including their demographics, vaccination type, RMD diagnosis, treatments, post-vaccine flares, and other adverse events. The control group consisted of healthy, vaccinated individuals.

Results: The ECR-VaXurvey3 included 890 vaccinated RMD patients, predominantly women (73.3%) with a mean age of 44.4 ± 12.1 years, and 172 controls. The RMD group comprised 816 (91.7%) with I-RMD and 74 (8.3%) with NI-RMD. The frequency of adverse events was comparable between the RMD and control groups. In RMD patients, injection site pain (59.9%) was the most reported adverse event. Post-vaccination COVID-19 infections and disease flares were reported in 2.9% and 12.1% of I-RMD patients and in 8.1% and 9.5% of NI-RMD patients (p = 0.018 and p = 0.497, respectively). The severity of prior COVID-19 infection (odds ratio (OR) = 2.4, 95% CI: 1.0-5.8; p = 0.040) and azathioprine use (OR = 2.6, 95% CI: 1.1-5.9; p = 0.024) were associated with higher post-vaccine adverse events, while biologic use was associated with fewer adverse events (OR = 0.5, 95% CI: 0.3-0.8; p = 0.010).

Conclusions: Adverse events following COVID-19 vaccinations in patients with RMD are comparable to controls.

查看原文本刊更多论文

在埃及风湿病和肌肉骨骼疾病患者接种COVID-19疫苗的安全性：一项横断面研究

目的调查炎症性和非炎症性风湿病和肌肉骨骼疾病（分别为 I-RMD 和 NI-RMD）患者接种 COVID-19 疫苗后不良事件的发生率和相关风险因素：埃及风湿病学院 COVID-19 研究小组调查了 2021 年 12 月至 2022 年 6 月期间接种 COVID-19 疫苗的 RMD 患者的医生报告数据（ECR-VaXurvey3），包括其人口统计学、疫苗接种类型、RMD 诊断、治疗、疫苗接种后复发和其他不良事件。对照组由接种过疫苗的健康人组成：ECR-VaXurvey3 包括 890 名接种过疫苗的 RMD 患者和 172 名对照组，前者主要为女性（73.3%），平均年龄为 44.4 ± 12.1 岁。RMD 组中有 816 名 I 型 RMD 患者（91.7%）和 74 名 NI 型 RMD 患者（8.3%）。RMD 组和对照组发生不良反应的频率相当。在 RMD 患者中，报告最多的不良反应是注射部位疼痛（59.9%）。2.9%和12.1%的I-RMD患者以及8.1%和9.5%的NI-RMD患者在接种COVID-19后出现感染和疾病复发（分别为p = 0.018和p = 0.497）。既往COVID-19感染的严重程度（几率比（OR）=2.4，95% CI：1.0-5.8；p=0.040）和硫唑嘌呤的使用（OR=2.6，95% CI：1.1-5.9；p=0.024）与疫苗接种后不良事件的增加有关，而生物制剂的使用与不良事件的减少有关（OR=0.5，95% CI：0.3-0.8；p=0.010）：RMD患者接种COVID-19疫苗后发生的不良事件与对照组相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊